ProMIS Q3 net loss $2.4M, cash $16.9M; starts Phase 1a PMN310 Alzheimer's trial

ProMIS Neurosciences Inc.

2023-Q3 EPS reported -$0.98

Net loss $2.4M in Q3 2023 vs $6.0M in Q3 2022; R&D expenses dropped to $1.1M from $4.6M.
Cash $16.9M at Sep 30, 2023, up from $5.9M at Dec 31, 2022, after $20.4M gross PIPE proceeds.
Phase 1a trial of PMN310 for Alzheimer's: first subjects dosing expected Nov 2023; early cohort results in H1 2024.
Raised $20.4M via private placement of ~10M shares and ~955K pre-funded warrants in August 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

ProMIS Neurosciences Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $2.4 million for the quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Net income: Net loss was $2.4 million for the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

ProMIS Neurosciences Inc. (the "Company") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the three and nine months ended September 30, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-019067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.